Develop and commercialize blood purification medical devices. Offer CytoSorb, an extracorporeal cytokine filter for critical care applications. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 15% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $37.1M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 39 buys and 11 sells. Management buying with its own money is usually read as a good sign.
A loss of $8.2M against $37.1M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CTSO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CTSO’s sales are going backwards, and it closed last year at a loss. The road back runs through both.